PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>Retatrutide>>research-evidence
Clinical-stage

Retatrutide Research Evidence: Trials to Know

The short list of retatrutide studies a reader should recognize, and what each contributed.

Phase 2 dose-ranging trial

The NEJM-published phase 2 (n=338) established the weight-reduction signal (~17.5% at 24 weeks, higher at 48 weeks with continued dosing) and the tolerability pattern that shaped phase 3 designs.

TRIUMPH phase 3 program

The registrational obesity series testing retatrutide against placebo at scale, including a dedicated obesity + T2D trial. Enrollment is registered on ClinicalTrials.gov, where primary results will post first.

Mechanistic literature

Preclinical triple-agonist work established the receptor profile and the glucagon-component hypotheses; the human mechanistic contribution is still being dissected from outcome data.

How to track it

ClinicalTrials.gov is the primary source (search "retatrutide"). Press releases and conference abstracts precede peer review; this catalog treats them as provisional.

Educational content only — not medical advice. This compound is not an approved medicine; no dosing guidance is or will be provided.

References

  1. ClinicalTrials.gov — registered retatrutide studies. [source]
  2. Newman JC, et al. Retatrutide phase 2 results. N Engl J Med 2023 (see trial record for details). [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement